CMS publishes patient guidance for the Medicare GLP-1 Bridge

CMS published beneficiary-facing guidance on July 13, 2026, spelling out how the Medicare GLP-1 Bridge works, including eligibility rules, the $50 flat copay, and which drugs are covered ^[1]. The short-term demonstration began July 1, 2026, and is now set to run through December 31, 2027 ^[1].

The Bridge sits outside the normal Medicare Part D benefit structure. CMS says Part D sponsors do not carry financial risk for these drugs and do not need to opt in for beneficiaries to get access ^[1]. Instead, CMS is using a single central processor to handle prior authorization, claims adjudication, and pharmacy payment ^[1]. That processor is Humana, according to a Medicare advisory site that tracks the program ^[2].

Eligible beneficiaries pay a flat $50 copay, but CMS's guidance flags several ways this differs from standard Part D coverage: the Part D deductible does not apply, none of the $50 copay counts toward a beneficiary's true out-of-pocket (TrOOP) costs, and there is no low-income subsidy for beneficiaries who normally qualify for Extra Help ^[1]. That means the copay stays at $50 for everyone, regardless of income-based subsidies that would otherwise lower costs ^[1][2].

According to the advisory site's breakdown, the drugs covered include Wegovy (semaglutide) in all formulations, Zepbound (tirzepatide) in its KwikPen formulation, and Foundayo (oral semaglutide) in all formulations, while Ozempic and Mounjaro remain covered only under standard Part D rules for type 2 diabetes ^[2]. That source also describes three clinical eligibility tiers tied to prior authorization: a BMI of 35 or higher alone; a BMI of 30 or higher with a condition such as heart failure, uncontrolled high blood pressure, or chronic kidney disease; or a BMI of 27 or higher with pre-diabetes, a prior heart attack or stroke, or peripheral artery disease ^[2]. CMS's own FAQ page does not list these specific tiers, so readers should confirm current criteria directly with CMS or their plan ^[1].

CMS says the program's legal basis comes from Section 402(a)(1)(A) of the Social Security Amendments of 1967, as extended to Part D, which lets the agency test payment and reimbursement changes meant to increase efficiency in Medicare-covered services ^[1]. CMS also says the Bridge was extended through the end of 2027 in part because a related, larger initiative called the BALANCE Model will not launch in 2027 as planned, and the extra time under the Bridge will let CMS collect more data on GLP-1 use to share with Part D plans ahead of any future BALANCE rollout ^[1].

Why it matters for patients

For beneficiaries who qualify, the $50 flat copay is a major change from typical Part D cost-sharing on GLP-1 drugs, where coinsurance can run 25% to 33% of list price — potentially $325 to $430 a month on a drug listed at roughly $1,300 ^[2]. But because the program operates outside normal Part D accounting, the $50 payments don't chip away at a beneficiary's annual out-of-pocket cap, and beneficiaries who normally get Extra Help through the low-income subsidy won't receive any additional discount below $50 ^[1][2]. Beneficiaries still need to be enrolled in a Part D or Medicare Advantage plan with drug coverage, and access still requires a doctor to submit paperwork verifying medical eligibility ^[1][2]. Coverage also depends on which drug and formulation is prescribed, since not every GLP-1 product on the market qualifies ^[1][2].

What happens next

The program runs through December 31, 2027 ^[1]. CMS says data gathered during this period will be shared with Part D plan sponsors as the agency considers whether to move forward with the broader BALANCE Model in Part D ^[1]. Beneficiaries with questions can call 1-800-MEDICARE or check Medicare.gov, and providers or pharmacies can submit technical questions to a dedicated CMS mailbox ^[1].